BRAF mutated patients had significantly higher expression of APRIL/TNFSF13 and CXCL10 in comparison to BRAF wild-type patients, while NRAS wild-type patients had higher expression of TNFSF13 in comparison to patients with melanomas harboring NRAS mutations (Figure S2B). This evidence concerns the gene CXCL10 and melanoma.